RNA sequencing results indicated that multiple KRAS-directed antineoplastic and immunomodulatory pathways were involved, while BN1-induced suppressions of MEK-ERK and PD-L1 were detected in human triple-negative breast cancer (TNBC) MDA-MB-231 cells (KRAS G13D mutation) and mouse TNBC 4T1 cells (wild-type KRAS overexpression). This evidence concerns the gene KRAS and triple-negative breast carcinoma.